Vue transversale de la maladie
Lupus
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
719 résultats correspondants
· 46 visibles sur cette page
dans le périmètre Lupus
Niveau clinique
Études et traitements 248
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| SAR441344 IV NCT05039840 · APATURA — Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Syst… | Lupus | À vérifier | Phase 2 | ACTIVE_NOT_RECRUITING | This is a multinational, randomized, placebo-controlled, parallel treatmen… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:31 | Détail |
| ABBV-319 NCT06977724 · A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effect… | Lupus | Immunomodulation · Traitement symptomatique | Phase 1 | RECRUITING | Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disea… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| Anifrolumab NCT06795893 · The Anifrolumab PRIM Program | Lupus | À vérifier | À vérifier | RECRUITING | This is an observational study, in which the main research question is to… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| Cevostamab NCT07629583 · To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythe… | Lupus | À vérifier | Phase 1 | RECRUITING | The study will evaluate the safety, tolerability, pharmacokinetics, and ph… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| Creating Health Course Study for People With Rheumatological Conditio… NCT07180537 · NCT07180537 | Lupus | Traitement symptomatique | Non applicable | RECRUITING | The goal of this project is to critically evaluate the effectiveness of an… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| DZP NCT06617325 · PHOENYCS FLY — A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pego… | Lupus | À vérifier | Phase 3 | RECRUITING | The purpose of this study is to evaluate the ability of dapirolizumab pego… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| ESG206 NCT07760155 · A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibod… | Lupus | À vérifier | Phase 2 | NOT_YET_RECRUITING | This is a multicenter, randomized, double-blind, placebo-controlled Phase… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| HEAL-SLE: Holistic Energy for Alleviating Lupus Symptoms NCT07203157 · NCT07203157 | Lupus | Traitement symptomatique | Non applicable | ACTIVE_NOT_RECRUITING | The purpose of this study is to assess the efficacy, feasibility, and acce… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| HN2301 injection NCT06801119 · SLE，SSc，RA — Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs） | Lupus | À vérifier | Phase 1 | RECRUITING | This is an open lable and single arm study, is designed to evaluate the sa… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| HN2302 Injection NCT07523282 · AID — Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Dise… | Lupus | À vérifier | Phase 1 | NOT_YET_RECRUITING | This is an open-label, single-arm study designed to evaluate the safety an… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| Ia:QLS2404 very low dose NCT07751315 · A Study of QLS2404 Injection in Healthy Participants and Participants With Rheum… | Lupus | À vérifier | Phase 1 | NOT_YET_RECRUITING | This study consists of a randomized, double-blind, placebo-controlled Phas… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| IASO-782 injection NCT07483346 · IASO-782 in Systemic Lupus Erythematosus | Lupus | À vérifier | Phase 1 | RECRUITING | his study is a randomized, double-blinded, and placebo-controlled phase Ia… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| Inebilizumab NCT06570798 · A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune… | Lupus | À vérifier | Phase 2 | RECRUITING | The main objective is to assess the safety and tolerability of inebilizuma… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| Kidney Biopsy NCT07760480 · MAPLE — Assessing Residual Inflammation and Macrophage Presence in Lupus Nephrit… | Lupus | Immunomodulation · Thérapie génique | Phase 4 | RECRUITING | The goal of this clinical trial is to learn how different treatments affec… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| MK-6194 NCT06161116 · Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythem… | Lupus | À vérifier | Phase 2 | TERMINATED | The purpose of this study is to evaluate the efficacy and safety of MK-619… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| PF-06823859 NCT05879718 · A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CL… | Lupus | Traitement symptomatique · Thérapie génique | Phase 2 | TERMINATED | The purpose of this study is to learn about the effects, safety and how PF… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| PREPCOV — Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine… NCT04481633 · NCT04481633 | Lupus | À vérifier | Non applicable | COMPLETED | There is a pandemic in the world by COVID-19. Currently, the pharmacologic… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| Quinacrine Hydrochloride NCT07694336 · A Study of Quinacrine in Participants With Cutaneous Lupus Erythematosus | Lupus | Immunomodulation · Traitement symptomatique · Thérapie génique | Phase 2 | RECRUITING | The research study is being conducted to learn more about how patients wit… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| SG301 SC Injection NCT06144710 · SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus | Lupus | À vérifier | Phase 1 | COMPLETED | This is a randomized, double-blind, placebo-controlled phase I clinical st… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| Vonsetamig NCT06975787 · Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupu… | Lupus | À vérifier | Phase 1 | RECRUITING | This study is researching a particular group of experimental drugs adminis… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
Découverte scientifique
Recherches et trouvailles 0
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune trouvaille ne correspond aux filtres. | |||||||
Bibliographie
Publications 465
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Pharmacokinetic Drug Interaction Studies of Limnetrelvir with Midazol… Ia:QLS2404 Max dose · PMID 42133202 | Lupus | À vérifier | Publication | PubMed | Voir la publication source Limnetrelvir is an oral inhibitor of the SARS-CoV-2 main protease (Mpro) and was developed with the aim of achieving br… | Clinical drug investigation 2026-08-16 13:22:29 | Source |
| Application of 18-glycyrrhetinic acid Fluorescent probes in cell imag… Ia:QLS2404 high dose · PMID 41797643 | Lupus | Immunomodulation | Publication | PubMed | Voir la publication source Fluorescently labelled small molecule probes (fluorescent probes) play an important role in cell imaging and are often… | Journal of enzyme inhibition and medicinal chemistry 2026-08-16 13:22:26 | Source |
| Transradial versus transfemoral access for diagnostic cerebral angiog… Ia:QLS2404 middle dose · PMID 42155301 | Lupus | Traitement symptomatique · Thérapie génique | Publication | PubMed | Voir la publication source To compare system-reported radiation metrics and diagnostic outcomes of right transradial access (TRA) versus transfemo… | Clinical neurology and neurosurgery 2026-08-16 13:22:25 | Source |
| Comprehensive evaluation of GdO reinforced polyhydroxybutyrate as a h… Ia:QLS2404 very low dose · PMID 42365836 | Lupus | À vérifier | Publication | PubMed | Voir la publication source In this study, the shielding properties of biodegradable polyhydroxybutyrate composites reinforced with various amounts… | Applied radiation and isotopes : including data, instr… 2026-08-16 13:22:24 | Source |
| Pain perception and patient tolerance to intra-articular ozone-oxygen… Ia:QLS2404 very low dose · PMID 42230177 | Lupus | Traitement symptomatique | Publication | PubMed | Voir la publication source This study aimed to investigate pain perception and patients' tolerance to intra-articular medical ozone (IA-MO) inject… | Journal of cranio-maxillo-facial surgery : official pu… 2026-08-16 13:22:24 | Source |
| Atypical Lymphocytosis Induced by T Cell-Engaging Therapy in Patients… Cevostamab · PMID 41013982 | Lupus | Immunomodulation | Publication | PubMed | Voir la publication source Atypical lymphocytes (ALYs) are activated lymphocytes with distinct morphological characteristics, often observed in va… | International journal of laboratory hematology 2026-08-16 13:22:23 | Source |
| Psychiatric comorbidities cluster early after onset in MOGAD: a cross… Inebilizumab · PMID 41956817 | Lupus | Remyélinisation · Immunomodulation | Publication | PubMed | Voir la publication source Psychiatric comorbidities are increasingly recognised in demyelinating diseases, yet their frequency and timing in myel… | Journal of neurology, neurosurgery, and psychiatry 2026-08-16 13:22:20 | Source |
| Outcomes and Predictors of Treatment Response in Patients With Pure L… Mycophenolate Mofetil (MMF) Treatment · PMID 42494786 | Lupus | Immunomodulation | Publication | PubMed | Voir la publication source The indications and modalities of therapeutic strategies for first-onset pure lupus membranous nephropathy (PLMN) remai… | Kidney international reports 2026-08-16 13:22:09 | Source |
| Prednisolone modulates CD8⁺ and regulatory T-cell activity to dampen… Prednisolone · PMID 41807927 | Lupus | Ralentissement de la progression | Publication | PubMed | Voir la publication source Immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced melanoma, yet their efficacy is limited… | Oncoimmunology 2026-08-16 13:22:09 | Source |
| Shared genetics of IgA nephropathy and cardiometabolic diseases revea… Prednisolone · PMID 42535737 | Lupus | À vérifier | Publication | PubMed | Voir la publication source Immunoglobulin A nephropathy (IgAN), the most common primary glomerular disease and a leading cause of end-stage kidney… | Renal failure 2026-08-16 13:22:09 | Source |
| Temporary mycophenolate discontinuation and reintroduction in pediatr… Mycophenolate Mofetil (MMF) Treatment · PMID 41979713 | Lupus | À vérifier | Publication | PubMed | Voir la publication source Temporary discontinuation of mycophenolate mofetil (MMF) is frequently required in pediatric kidney transplant recipien… | Pediatric nephrology (Berlin, Germany) 2026-08-16 13:22:09 | Source |
| Complication rates of 16- and 18-gauge needles for native kidney biop… Kidney Biopsy · PMID 42185739 | Lupus | À vérifier | Publication | PubMed | Voir la publication source This systematic review and meta-analysis evaluated complication rates and diagnostic yield reported in studies of adult… | Renal failure 2026-08-16 13:22:05 | Source |
| Erythropoietin receptor upregulation is associated with tubular injur… Kidney Biopsy · PMID 41947411 | Lupus | À vérifier | Publication | PubMed | Voir la publication source This study aimed to investigate erythropoietin receptor (EPOR) expression in human AKI and to examine its association w… | Renal failure 2026-08-16 13:22:05 | Source |
| Successful treatment of idiopathic multicentric Castleman disease wit… Kidney Biopsy · PMID 42310940 | Lupus | Traitement symptomatique | Publication | PubMed | Voir la publication source Idiopathic multicentric Castleman disease (iMCD) is a rare hematological disease of heterogenous presentation, with sym… | Renal failure 2026-08-16 13:22:05 | Source |
| Dynamics of complete responses (CRs) in patients with relapsed or ref… Odronextamab · PMID 42007452 | Lupus | Ralentissement de la progression · Immunomodulation · Thérapie génique | Publication | PubMed | Voir la publication source Complete response (CR) is an important treatment goal in follicular lymphoma (FL). In relapsed or refractory (R/R) FL,… | HemaSphere 2026-08-16 13:21:59 | Source |
| Anifrolumab versus Belimumab for Cardiovascular Disease Risk in Syste… Anifrolumab · PMID 42565362 | Lupus | À vérifier | Publication | PubMed | Voir la publication source Current guidelines recommend anifrolumab and belimumab as comparably viable immunosuppressive therapies for active syst… | Arthritis & rheumatology (Hoboken, N.J.) 2026-08-16 13:21:55 | Source |
| Therapeutic Approaches for Cutaneous Lupus Erythematosus: a Changing… Litifilimab · PMID 41890817 | Lupus | À vérifier | Publication | PubMed | Voir la publication source Cutaneous lupus erythematosus (CLE) is an autoimmune skin disease that can occur with or without systemic lupus erythem… | Journal of inflammation research 2026-08-16 13:21:55 | Source |
| Use of support vector machines for disease risk prediction in genome-… Deciphering the Genetic Architecture of Autoimmune Diseases · PMID 22777693 | Lupus | À vérifier | Publication | PubMed | Voir la publication source The success of genome-wide association studies (GWAS) in deciphering the genetic architecture of complex diseases has f… | Human mutation 2026-08-16 13:21:54 | Source |
| FDA-approved IMPDH inhibitors synergize with ribavirin to inhibit res… Mycophenolate Mofetil · PMID 41770611 | Lupus | À vérifier | Publication | PubMed | Voir la publication source ABSTRACTRespiratory syncytial virus (RSV), a leading cause of severe lower respiratory tract infections in pediatric an… | Emerging microbes & infections 2026-08-16 13:21:50 | Source |
| Laparoscopic Ultrasound-Guided Biopsy: A Safe and Effective Approach… Mycophenolate Mofetil · PMID 41674067 | Lupus | Immunomodulation | Publication | PubMed | Voir la publication source Idiopathic retroperitoneal fibrosis (IRPF) is a rare fibroinflammatory condition that is challenging to distinguish fro… | Journal of investigative surgery : the official journa… 2026-08-16 13:21:50 | Source |
Exploration — prudence
Pistes exploratoires 6
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Lupus | Neuroprotection · Immunomodulation | Hypothèse exploratoire | Rapprochement automatique non validé | Modulation immunométabolique de la microglie 4-octyl itaconate et dérivés est étudié dans Sclérose latérale amyotrophique et documente plusieurs axes biologiques po… | Rapprochement Biomedical Watch · Sclérose latérale amy… | Détail |
| Bavisant BRAVEinMS — Bavisant | Lupus | Remyélinisation · Neuroprotection · Immunomodulation | Hypothèse exploratoire | Rapprochement automatique non validé | Antagonisme du récepteur H3 de l’histamine Bavisant est étudié dans Sclérose en plaques et documente plusieurs axes biologiques pouvant être pertinents pour Lupus… | Rapprochement Biomedical Watch · Sclérose en plaques | Détail |
| Vecteur Ple389 (ADORA2A) MiniPromoter Ple389 — ciblage striatal | Lupus | Thérapie génique | Hypothèse exploratoire | Rapprochement automatique non validé | Expression génique ciblée dans les neurones striataux Vecteur Ple389 (ADORA2A) est étudié dans Maladie de Huntington et documente plusieurs axes biologiques pouvant être per… | Rapprochement Biomedical Watch · Maladie de Huntington | Détail |
| Tol-MP Tol-MP — tolérance immunitaire spécifique de la myéline | Lupus | Neuroprotection · Immunomodulation | Hypothèse exploratoire | Rapprochement automatique non validé | Microparticules biodégradables chargées en rapamycine et fonctionnalisées… Tol-MP est étudié dans Sclérose en plaques et documente plusieurs axes biologiques pouvant être pertinents pour Lupus :… | Rapprochement Biomedical Watch · Sclérose en plaques | Détail |
| SetPoint System SetPoint System — SetPoint Medical | Lupus | Immunomodulation | Hypothèse exploratoire | Rapprochement automatique non validé | re ApplicationsPublicationsCompanyCareersNewsGet startedGet startedNewsThe… SetPoint System est étudié dans Sclérose en plaques et documente plusieurs axes biologiques pouvant être pertinents pou… | Rapprochement Biomedical Watch · Sclérose en plaques | Détail |
| Thonningianin A Thonningianin A — neuroprotection anti-amyloïde | Lupus | Neuroprotection | Hypothèse exploratoire | Rapprochement automatique non validé | Modulation du stress oxydatif et des protéines associées à Alzheimer Thonningianin A est étudié dans Maladie d’Alzheimer et documente plusieurs axes biologiques pouvant être pertinents pou… | Rapprochement Biomedical Watch · Maladie d’Alzheimer | Détail |